Head of the Laboratory Marzia Bedoni received her MSc degree in Biological Sciences in 2004 and her PhD degree in Morphological Science in 2007 (University of Milan). From 2007 to 2010 she carried out her Post-Doctorate at the Laboratory of Nanomedicine and Biophotonics (LABION) of FDG granted by the Cariplo Foundation, Seed Capital and Seventh Framework Programme. From January 2011 she is permanent researcher in FDG. During her research activity at LABION she has worked on multiple project: i) nano-biophotonics for the characterisation of exosomes as regenerative rehabilitation markers; ii) biophotonics application for diagnosis and therapy monitoring in neurodegenerative diseases (Alzheimer’s disease and Amyotrophic Lateral Sclerosis), skin diseases (psoriasis, cancer), leukemia and; iii) nanoparticles toxicity on human skin biology; iv) biocompatibility in transdermal drug delivery and dry electrodes devices. From 2007 she is also lecturer in Human Anatomy for the Faculty of Medicine and Surgery at the University of Milan. She received some awards during international congresses for her research studies. She is author of several papers published in peer-reviewed scientific journals , abstracts for national and international congresses and she is also co-inventor of 4 patents. She is board member of the “Society for Cutaneous Ultrastructure Research (SCUR)”, and ordinary member of the “European Society of Dermatological Research” and the “Italian Society of Human Anatomy”. She is involved in several national and international projects. Email: firstname.lastname@example.org
Alice Gualerzi received her Master’s degree in Biology applied to biomedical research in 2009 and her PhD degree in Morphological Sciences in 2013 at the University of Milan, focusing her research on the morphological analysis of skin and oral mucosa after exposure to exogenous stimuli in a 3D culture model. In 2012 she collaborated for six months as Junior Research Specialist with Dr. Chia-Ling Tu the University of California San Francisco and she was later granted with a postdoctoral scholarship funded by Sardegna Ricerche to work at BT (Biomedical Tissues) srl c/o Parco scientifico e tecnologico Polaris (Pula, CA) in the field of cardiovascular tissue engineering, regenerative medicine, and nanotoxicity. She joined LABION in 2014 and the main focuses of her research are: i) biophotonic characterization of extracellular vesicles from mesenchymal stem cells to be used as regenerative agents and plasma exosomes as diagnostic and prognostic biomarkers for regenerative rehabilitation; (ii) Raman spectroscopy for the characterization of cells and tissues in health, pathology and for nanotoxicology purposes. She is author of several papers published in peer-reviewed scientific journals and of several abstracts for national and international congresses.
Silvia Picciolini graduated in pharmaceutical chemistry and technologies (CTF) at the University of Milan on March 2014. She spent one year at FDG doing research experience for her experimental thesis in collaboration with a spin off of the Joint Research Centre (Ispra) aimed at the optimization of nanohole arrays as solid SERS substrates for the detection of genetic biomarkers of acute myeloid leukemia (AML), in order to evaluate the minimal residual disease. She was granted with an AXA scholarship for the Raman analysis of lipids in the blood of Alzheimer’s patients. In 2019, she has completed her PhD in Translational and Molecular Medicine at University of Milano-Bicocca working at LABION on a project aimed at the detection and characterization of neuronal extracellular vesicles from human plasma, in order to identify their role in the pathogenesis of Alzheimer’s disease (AD). In particular, the intent was to design a SPRi based biosensor for the simultaneous detection of these multiple complex circulating biomarkers using an extremely limited amount of peripheral blood. Now, she is applying the optimized SPRi platform for the rehabilitation monitoring of stroke patients. She is also working on the biophotonics characterization of liposomes as therapeutic agents for neurological diseases (NEVERMIND project). She is co-author of several publications in international peer-reviewed journals and abstracts of national and international conferences.
Cristiano Carlomagno received his Master’s Degree in Molecular and Industrial Biotechnology at University of Perugia in 2014 with a research focused on the synthesis and characterization of functionalized mesoporous silica nanoparticles used as drug delivery devices. In 2018 he completed his PhD in Industrial Engineering achieved at the University of Trento with a research on the synthesis and characterization of bioactive micropatterned ceramics with enhanced osteoinductivity for bone regeneration. During his PhD he was involved also in projects regarding the synthesis of ceramic SERS substrates and biodegradable multi-drug delivery systems for biomedical applications. He collaborated with the University of Texas at Arlington and Dallas regarding the biological and spectroscopical characterization of bioactive ceramics and with the Chonbuk National University (South Korea) for the synthesis of injectable hydrogels for tissue engineering applications. He is actually a research collaborator at Labion working on the detection through SPR, Raman spectroscopy and MALDI-TOF of new potential biomarkers for the diagnosis of neural disorders.
Francesca Rodà received her Master’s Degree in Pharmaceutical Chemistry and Technologies (CTF) at the University of Turin in July 2020. She made her sperimental thesis at Advanced Pharmaceutical Nanotechnologies Laboratory (DSTF-UniTO) working on the evaluation of the effect of lyoprotectant substances in the freeze-drying of liposomes. Currently, she is working with nanotechnologies and advanced biophotonics to study the diseases of the central nervous system and to evaluate the efficacy of pharmacological and rehabilitation therapies.
Furio Gramatica, designer and founder of LABION and responsible of the laboratory until 2017, he is currently Head of the Innovation Unit at Don Gnocchi Foundation. For five years he served as Director of the Biomedical Technology Department “Polo Tecnologico” in the same Foundation. Formerly, he spent several years at CERN (Geneva), at Italian Institute of Nuclear Physics and in high-technology companies, with R&D management roles. Dr. Gramatica is fellow professor of physics at Milan University Medical School, Chair of the Working Group Clinical Interface, Executive Board Member of the European Technology Platform of Nanomedicine, evaluator and reviewer of the European Commission and of Wellcome Trust.